#391 ‒ Colorectal Cancer Screening: Importance of Early Screening, Colonoscopy as a Screening and Preventive Tool, and How to Build a Personalized Strategy

Colorectal cancer remains the United States' second leading cause of cancer death, accounting for roughly 55,000 fatalities annually. Because the disease follows a slow, decade‑long progression from benign polyp to malignancy, it is uniquely amenable to early detection and removal. Peter Attia emphasizes that colonoscopy is the only screening tool that both visualizes and excises precancerous lesions, a capability that underpins the CDC’s estimate that 68 % of CRC deaths could be avoided with appropriate screening. This dual diagnostic‑therapeutic function makes colonoscopy the cornerstone of preventive oncology.

Recent data reveal a troubling surge in early‑onset colorectal cancer among adults in their thirties and forties, prompting calls for earlier screening initiation. Attia walks listeners through optimal bowel preparation, noting that modern split‑dose regimens dramatically improve mucosal visibility and lower polyp miss rates. He also stresses that colonoscopy quality metrics—such as adenoma detection rate—should guide personalized screening intervals, rather than a one‑size‑fits‑all schedule. By aligning interval length with individual risk factors and exam quality, clinicians can maximize prevention while minimizing unnecessary procedures.

While stool‑based DNA tests and emerging blood‑based biomarkers offer convenient, non‑invasive alternatives, Attia cautions that they cannot replace the therapeutic advantage of colonoscopy. These tests excel at risk stratification but miss the opportunity to remove lesions during the same encounter. He advises patients to view them as complementary—useful for those unable or unwilling to undergo endoscopy, yet followed by a colonoscopy if results are positive or if personal risk is elevated. Ultimately, a balanced strategy that leverages high‑quality colonoscopy alongside appropriate non‑invasive screening can drive CRC mortality toward the projected near‑zero target.